Recursion Pharmaceuticals (RXRX) Common Equity (2020 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Common Equity came in at $1.0 billion in Q1 2026, up 9.72% YoY from $933.9 million in Q1 2025, and down 9.38% on a QoQ basis from $1.1 billion in Q4 2025.
Recursion Pharmaceuticals (RXRX) Common Equity (2020 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 7 years of Common Equity data on file, last reported at $1.0 billion in Q1 2026.
- Quarterly Common Equity rose 9.72% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 9.72% YoY) and the FY2025 annual result came in at $1.1 billion, up 9.29% from the prior year.
- Common Equity declined to $1.0 billion in Q1 2026, from $1.1 billion in the prior quarter.
- In the past five years, Common Equity ranged from a high of $1.1 billion in Q4 2025 to a low of $388.0 million in Q3 2022.
- A 5-year average of $659.2 million and a median of $493.6 million in 2022 frame the typical range for Common Equity.
- The widest YoY moves for Common Equity: up 311.8% in 2022, down 35.22% in 2022.
- Tracing RXRX's Common Equity over 5 years: stood at $485.8 million in 2022, then dropped by 4.6% to $463.4 million in 2023, then soared by 123.28% to $1.0 billion in 2024, then grew by 9.29% to $1.1 billion in 2025, then fell by 9.38% to $1.0 billion in 2026.
- The last three Common Equity figures came in at $1.0 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn | 915.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 915.00 Mn |
| Mar 31, 2026 | 1.02 Bn |
| Dec 31, 2025 | 1.13 Bn |
| Sep 30, 2025 | 1.05 Bn |
| Jun 30, 2025 | 919.15 Mn |
| Mar 31, 2025 | 933.95 Mn |
| Dec 31, 2024 | 1.03 Bn |
| Sep 30, 2024 | 524.56 Mn |
| Jun 30, 2024 | 584.45 Mn |
| Mar 31, 2024 | 401.15 Mn |
| Dec 31, 2023 | 463.44 Mn |
| Sep 30, 2023 | 437.97 Mn |
| Jun 30, 2023 | 468.96 Mn |
| Mar 31, 2023 | 430.18 Mn |
| Dec 31, 2022 | 485.81 Mn |
| Sep 30, 2022 | 388.03 Mn |
| Jun 30, 2022 | 437.58 Mn |
| Mar 31, 2022 | 493.57 Mn |
| Dec 31, 2021 | 542.94 Mn |
| Sep 30, 2021 | 599.03 Mn |